Weinberg, Daniel N.
Papillon-Cavanagh, Simon
Chen, Haifen
Yue, Yuan
Chen, Xiao
Rajagopalan, Kartik N.
Horth, Cynthia
McGuire, John T.
Xu, Xinjing
Nikbakht, Hamid
Lemiesz, Agata E.
Marchione, Dylan M.
Marunde, Matthew R.
Meiners, Matthew J.
Cheek, Marcus A.
Keogh, Michael-Christopher
Bareke, Eric
Djedid, Anissa
Harutyunyan, Ashot S.
Jabado, Nada
Garcia, Benjamin A.
Li, Haitao
Allis, C. David
Majewski, Jacek
Lu, Chao
Article History
Received: 30 August 2018
Accepted: 6 August 2019
First Online: 4 September 2019
Competing interests
: EpiCypher (M.R.M., M.J.M., M.A.C. and M.-C.K.) is a commercial developer and supplier of platforms similar to those used in this study: recombinant semi-synthetic modified nucleosomes and the dCypher nucleosome-binding assay.